Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes

Ida Azizkhanian, Olgica Trenchevska, Yara Bashawri, Jiaqi Hu, Juraj Koska, Peter D. Reaven, Randall W. Nelson, Dobrin Nedelkov, Hussein N. Yassine

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Apolipoprotein A-II (apoA-II) is the second most abundant protein in high-density lipoprotein particles. However, it exists in plasma in multiple forms. The effect of diabetes on apoA-II proteoforms is not known. Objective: Our objective was to characterize plasma apoA-II proteoforms in participants with and without type 2 diabetes. Methods: Using a novel mass spectrometric immunoassay, the relative abundance of apoA-II proteoforms was examined in plasma of 30 participants with type 2 diabetes and 25 participants without diabetes. Results: Six apoA-II proteoforms (monomer, truncated TQ monomer, truncated Q monomer, dimer, truncated Q dimer, and truncated 2Qs dimer) and their oxidized proteoforms were identified. The ratios of oxidized monomer and all oxidized proteoforms to the native apoA-II were significantly greater in the diabetic group (P = .004 and P = .005, respectively) compared with the nondiabetic group. Conclusion: The relative abundance of oxidized apoA-II is significantly increased in type 2 diabetes.

Original languageEnglish (US)
JournalJournal of Clinical Lipidology
DOIs
StateAccepted/In press - Nov 3 2015

Fingerprint

Apolipoprotein A-II
Post Translational Protein Processing
Type 2 Diabetes Mellitus
HDL Lipoproteins
Immunoassay

Keywords

  • Apolipoprotein A-II
  • Diabetes
  • Mass spectrometry
  • Oxidations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Cite this

Azizkhanian, I., Trenchevska, O., Bashawri, Y., Hu, J., Koska, J., Reaven, P. D., ... Yassine, H. N. (Accepted/In press). Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2016.03.001

Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes. / Azizkhanian, Ida; Trenchevska, Olgica; Bashawri, Yara; Hu, Jiaqi; Koska, Juraj; Reaven, Peter D.; Nelson, Randall W.; Nedelkov, Dobrin; Yassine, Hussein N.

In: Journal of Clinical Lipidology, 03.11.2015.

Research output: Contribution to journalArticle

Azizkhanian, I, Trenchevska, O, Bashawri, Y, Hu, J, Koska, J, Reaven, PD, Nelson, RW, Nedelkov, D & Yassine, HN 2015, 'Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes', Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2016.03.001
Azizkhanian, Ida ; Trenchevska, Olgica ; Bashawri, Yara ; Hu, Jiaqi ; Koska, Juraj ; Reaven, Peter D. ; Nelson, Randall W. ; Nedelkov, Dobrin ; Yassine, Hussein N. / Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes. In: Journal of Clinical Lipidology. 2015.
@article{793582f8b8ae42d7a06bbc158c5106db,
title = "Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes",
abstract = "Background: Apolipoprotein A-II (apoA-II) is the second most abundant protein in high-density lipoprotein particles. However, it exists in plasma in multiple forms. The effect of diabetes on apoA-II proteoforms is not known. Objective: Our objective was to characterize plasma apoA-II proteoforms in participants with and without type 2 diabetes. Methods: Using a novel mass spectrometric immunoassay, the relative abundance of apoA-II proteoforms was examined in plasma of 30 participants with type 2 diabetes and 25 participants without diabetes. Results: Six apoA-II proteoforms (monomer, truncated TQ monomer, truncated Q monomer, dimer, truncated Q dimer, and truncated 2Qs dimer) and their oxidized proteoforms were identified. The ratios of oxidized monomer and all oxidized proteoforms to the native apoA-II were significantly greater in the diabetic group (P = .004 and P = .005, respectively) compared with the nondiabetic group. Conclusion: The relative abundance of oxidized apoA-II is significantly increased in type 2 diabetes.",
keywords = "Apolipoprotein A-II, Diabetes, Mass spectrometry, Oxidations",
author = "Ida Azizkhanian and Olgica Trenchevska and Yara Bashawri and Jiaqi Hu and Juraj Koska and Reaven, {Peter D.} and Nelson, {Randall W.} and Dobrin Nedelkov and Yassine, {Hussein N.}",
year = "2015",
month = "11",
day = "3",
doi = "10.1016/j.jacl.2016.03.001",
language = "English (US)",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes

AU - Azizkhanian, Ida

AU - Trenchevska, Olgica

AU - Bashawri, Yara

AU - Hu, Jiaqi

AU - Koska, Juraj

AU - Reaven, Peter D.

AU - Nelson, Randall W.

AU - Nedelkov, Dobrin

AU - Yassine, Hussein N.

PY - 2015/11/3

Y1 - 2015/11/3

N2 - Background: Apolipoprotein A-II (apoA-II) is the second most abundant protein in high-density lipoprotein particles. However, it exists in plasma in multiple forms. The effect of diabetes on apoA-II proteoforms is not known. Objective: Our objective was to characterize plasma apoA-II proteoforms in participants with and without type 2 diabetes. Methods: Using a novel mass spectrometric immunoassay, the relative abundance of apoA-II proteoforms was examined in plasma of 30 participants with type 2 diabetes and 25 participants without diabetes. Results: Six apoA-II proteoforms (monomer, truncated TQ monomer, truncated Q monomer, dimer, truncated Q dimer, and truncated 2Qs dimer) and their oxidized proteoforms were identified. The ratios of oxidized monomer and all oxidized proteoforms to the native apoA-II were significantly greater in the diabetic group (P = .004 and P = .005, respectively) compared with the nondiabetic group. Conclusion: The relative abundance of oxidized apoA-II is significantly increased in type 2 diabetes.

AB - Background: Apolipoprotein A-II (apoA-II) is the second most abundant protein in high-density lipoprotein particles. However, it exists in plasma in multiple forms. The effect of diabetes on apoA-II proteoforms is not known. Objective: Our objective was to characterize plasma apoA-II proteoforms in participants with and without type 2 diabetes. Methods: Using a novel mass spectrometric immunoassay, the relative abundance of apoA-II proteoforms was examined in plasma of 30 participants with type 2 diabetes and 25 participants without diabetes. Results: Six apoA-II proteoforms (monomer, truncated TQ monomer, truncated Q monomer, dimer, truncated Q dimer, and truncated 2Qs dimer) and their oxidized proteoforms were identified. The ratios of oxidized monomer and all oxidized proteoforms to the native apoA-II were significantly greater in the diabetic group (P = .004 and P = .005, respectively) compared with the nondiabetic group. Conclusion: The relative abundance of oxidized apoA-II is significantly increased in type 2 diabetes.

KW - Apolipoprotein A-II

KW - Diabetes

KW - Mass spectrometry

KW - Oxidations

UR - http://www.scopus.com/inward/record.url?scp=84963969074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963969074&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2016.03.001

DO - 10.1016/j.jacl.2016.03.001

M3 - Article

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

ER -